Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter

References

• Maher JJ. Retinol binding protein 4 and fatty liver: A direct link? Hepatology. 2013;58(2):477–479.
   PubMed Web of Science ®Google Scholar
• Tsutsumi C, Okuno M, Tannous L, et al. Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem. 1992;267:1805–1810.
   PubMed Web of Science ®Google Scholar
• Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6:79–87.
   PubMed Web of Science ®Google Scholar
• Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005 Jul 21;436(7049):356–362.
   PubMed Web of Science ®Google Scholar
• Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–733.
   PubMed Web of Science ®Google Scholar
• Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006 Jun 15;354(24):2552–2563.
   PubMed Web of Science ®Google Scholar
• Seo JA, Kim NH, Park SY, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf). 2008 Apr;68(4):555–560.
   PubMed Web of Science ®Google Scholar
• Stefan N, Hennige AM, Staiger H, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007 May;30(5):1173–1178.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alkhouri N, Alisi A, et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 May;7(5):575–579.
   PubMed Web of Science ®Google Scholar
• Frey SK, Nagl B, Henze A, et al. Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. Lipids Health Dis. 2008 Aug 27;7:29.
   PubMed Web of Science ®Google Scholar
• Iwasa M, Hara N, Miyachi H, et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat. 2009 Oct;16(10):716–723.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Lopez R, Berk M, et al. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2009;43(10):985–989. Nov-Dec.
   PubMed Web of Science ®Google Scholar
• Borgia SM, Hedskog C, Parhy B, et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis. 2018;218:1722–1729.
   PubMed Web of Science ®Google Scholar
• Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet. 2019;394:1451–1466.
   PubMed Web of Science ®Google Scholar
• Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol. 2016;22:1461–1476.
   PubMed Web of Science ®Google Scholar
• Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. 2002;35:937–946.
   PubMed Web of Science ®Google Scholar
• Lee H, Woo YJ, Kim SS, et al. Hepatitis C virus core protein overcomes all-trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-β2 expression via DNA methylation. Cancer Lett. 2013 Jul 28;335(2):372–379.
   PubMed Web of Science ®Google Scholar
• Imran M, Waheed Y, Manzoor S, et al. Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J. 2012 Jun;22(9):126.
   Google Scholar
• Petta S, Camma C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology. 2008 Jul;48(1):28–37.
   PubMed Web of Science ®Google Scholar
• Huang JF, Dai CY, Yu ML, et al. Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. J Hepatol. 2009 Mar;50(3):471–478.
   PubMed Web of Science ®Google Scholar
• Chang ML, Yeh CT, Lin DY, et al. Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation. BMC Med Genomics. 2009;2:51.
   PubMed Web of Science ®Google Scholar
• Chang ML, Chen JC, Yeh CT, et al. Topological and evolutional relationships between HCV core protein and hepatic lipid vesicles: studies in vitro and in conditionally transgenic mice. World J Gastroenterol. 2007;13:3472–3477.
   PubMed Web of Science ®Google Scholar
• Chang ML, Yeh CT, Chen JC, et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics. 2008;9:109.
   PubMed Web of Science ®Google Scholar
• Chang ML, Yeh HC, Tsou YK, et al. HCV core-induced nonobese hepatic steatosis is associated with hypoadiponectinemia and is ameliorated by adiponectin administration. Obesity (Silver Spring). 2012;20:1474–1480.
   PubMed Web of Science ®Google Scholar
• Chen WT, Lee MS, Chang CL, et al. Retinol-binding protein-4 expression marks the short-term mortality of critically ill patients with underlying liver disease: lipid, but not glucose, matters. Sci Rep. 2017;7(1):2881.
   PubMedGoogle Scholar
• Cheng YT, Cheng JS, Lin CH, et al. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study. Clin Microbiol Infect. 2020;26(3):366–372.
   PubMed Web of Science ®Google Scholar
• Chang ML, Kuo CJ, Pao LH, et al. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance. Virulence. 2017;8(7):1255–1264.
   PubMed Web of Science ®Google Scholar
• Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• Chang ML, Liang KH, Ku CL, et al. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep. 2016;6:30799.
   PubMed Web of Science ®Google Scholar
• Ram J, Snehalatha C, Selvam S, et al. Retinol binding protein-4 predicts incident diabetes in Asian Indian men with prediabetes. Biofactors. 2015;41(3):160–165.
   PubMed Web of Science ®Google Scholar
• Majerczyk M, Kocełak P, Choręza P, et al. Components of metabolic syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65 years and older. J Endocrinol Invest. 2018;41(10):1211–1219.
   PubMed Web of Science ®Google Scholar
• Rocha M, Bañuls C, Bellod L, et al. Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients [published correction appears. PLoS One. 2013;8:12.
   Web of Science ®Google Scholar
• Henze A, Frey SK, Raila J, et al. Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes. 2008;57(12):3323–3326.
   PubMed Web of Science ®Google Scholar
• Faria SS, Fernandes PC Jr, Silva MJ, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years After HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264–1278.e4.
   PubMed Web of Science ®Google Scholar
• Tacke F, Weiskirchen R, Trautwein C. Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis. Hepatology. 2008;48(5):1724–1726.
   PubMed Web of Science ®Google Scholar
• Qin S, Zhou Y, Lok AS, et al. SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics. 2012;12(8):1244–1252.
   PubMed Web of Science ®Google Scholar
• Chang ML, Cheng JS, Chien RN, et al. Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18(9):2064–2072.
   PubMed Web of Science ®Google Scholar
• Jang TY, Yeh ML, Huang CI, et al. Association of hyperuricemia with disease severity in chronic hepatitis C patients. PLoS One. 2018;13(11):e0207043.
   PubMed Web of Science ®Google Scholar
• Ribel-Madsen R, Friedrichsen M, Vaag A, et al. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes. 2009;58(1):54–60.
   PubMed Web of Science ®Google Scholar
• Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29(11):2457–2461.
   PubMed Web of Science ®Google Scholar
• Kataria Y, Deaton RJ, Enk E, et al. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016;16:30.
   PubMed Web of Science ®Google Scholar
• Gouthamchandra K, Kumar A, Shwetha S, et al. Serum proteomics of hepatitis C virus infection reveals retinol-binding protein 4 as a novel regulator. J Gen Virol. 2014;95(Pt 8):1654–1667.
   PubMedGoogle Scholar
• Li G, Esangbedo IC, Xu L, et al. Childhood retinol-binding protein 4 (RBP4) levels predicting the 10-year risk of insulin resistance and metabolic syndrome: the BCAMS study. Cardiovasc Diabetol. 2018;17(1):69.
   PubMedGoogle Scholar
• Mihm S. Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes. Dig Dis. 2010;28(1):280–284.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15(2):129–136.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Lagathu C, Lake JE, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48.
   PubMed Web of Science ®Google Scholar
• Schindler K, Haider D, Wolzt M, et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. Eur J Clin Invest. 2006;36(9):640–646.
   PubMed Web of Science ®Google Scholar
• Kotzé SR, Zinyama-Gutsire R, Kallestrup P, et al. HIV and schistosomiasis in rural Zimbabwe: the association of retinol-binding protein with disease progression, inflammation and mortality. Int J Infect Dis. 2015;33:159–164.
   PubMed Web of Science ®Google Scholar
• Lavinya AA, Lee CS, Hashim OH, et al. Proteomics analysis of blood plasma in HIV-infected patients with chronic kidney disease. Clin Biochem. 2019;73:90–97.
   PubMed Web of Science ®Google Scholar
• Peraire J, López-Dupla M, Alba V, et al. HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma. Clin Microbiol Infect. 2015;21(7):711.e1-711.e7118.
   PubMedGoogle Scholar
• Chan A, Park L, Collins LF, et al. Correlation between tenofovir drug levels and the renal biomarkers RBP-4 and ß2M in the ION-4 study cohort. Open Forum Infect Dis. 2019;6(1):ofy273.
   PubMed Web of Science ®Google Scholar